IGEC2: A 17-month search for gravitational wave bursts in 2005-2007

We present here the results of a 515 days long run of the IGEC2 observatory, consisting of the four resonant mass detectors ALLEGRO, AURIGA, EXPLORER and NAUTILUS. The reported results are related to the fourfold observation time from Nov. 6 2005 until Apr. 14 2007, when Allegro ceased its operation. This period overlapped with the first long term observations performed by the LIGO interferometric detectors. The IGEC observations aim at the identification of gravitational wave candidates with high confidence, keeping the false alarm rate at the level of 1 per century, and high duty cycle, namely 57% with all four sites and 94% with at least three sites in simultaneous observation. The network data analysis is based on time coincidence searches over at least three detectors: the four 3-fold searches and the 4-fold one are combined in a logical OR. We exchanged data with the usual blind procedure, by applying a unique confidential time offset to the events in each set of data. The accidental background was investigated by performing sets of 10^8 coincidence analyses per each detector configuration on off-source data, obtained by shifting the time series of each detector. The thresholds of the five searches were tuned so as to control the overall false alarm rate to 1/century. When the confidential time shifts was disclosed, no gravitational wave candidate was found in the on-source data. As an additional output of this search, we make available to other observatories the list of triple coincidence found below search thresholds, corresponding to a false alarm rate of 1/month.Comment: 10 pages, 8 figures Accepted for publication on Phys. Rev.

Results of the IGEC-2 search for gravitational wave bursts during 2005

The network of resonant bar detectors of gravitational waves resumed coordinated observations within the International Gravitational Event Collaboration (IGEC-2). Four detectors are taking part in this collaboration: ALLEGRO, AURIGA, EXPLORER and NAUTILUS. We present here the results of the search for gravitational wave bursts over 6 months during 2005, when IGEC-2 was the only gravitational wave observatory in operation. The network data analysis implemented is based on a time coincidence search among AURIGA, EXPLORER and NAUTILUS, keeping the data from ALLEGRO for follow-up studies. With respect to the previous IGEC 1997-2000 observations, the amplitude sensitivity of the detectors to bursts improved by a factor about 3 and the sensitivity bandwidths are wider, so that the data analysis was tuned considering a larger class of detectable waveforms. Thanks to the higher duty cycles of the single detectors, we decided to focus the analysis on three-fold observation, so to ensure the identification of any single candidate of gravitational waves (gw) with high statistical confidence. The achieved false detection rate is as low as 1 per century. No candidates were found.Comment: 10 pages, to be submitted to Phys. Rev.

Early progression as a predictor of survival in marginal zone lymphomas: An analysis from the FIL-NF10 study

Marginal zone lymphomas (MZLs) are indolent nonfollicular B-cell lymphomas (INFLs) and have heterogeneous clinical behavior. Recently, time to progression of disease at 24 months (POD24) was identified to stratify overall survival (OS) in follicular non-Hodgkin lymphoma and in INFL. Here, we examined the ability of POD24 to predict subsequent OS in a large, international cohort of MZL as part of the NF10 prospective international registry headed by Fondazione Italiana Linfomi (FIL). POD24 was only calculated for MZL patients requiring immediate therapy and was defined as experiencing lymphoma progression within 24 months from diagnosis. Among the 1325 patients enrolled in the NF10 study, we identified 321 patients with MZL for whom immediate therapy was planned right after lymphoma diagnosis. Overall, POD24 was confirmed in 59 patients (18%). Three-year OS for patients with POD24 was 53% with a hazard ratio of 19.5 (95% confidence interval, 8.4-45) compared with patients without POD24 (3-year OS, 95%). Association of POD24 with OS was confirmed for the subgroup of splenic and extranodal MZLs. Assessment of POD24 stratifies subsequent outcome inMZL and identifies a high-risk population

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: A GIMEMA, ERIC and UK CLL FORUM study

We performed an observational study on the efficacy of bendamustine and rituximab (BR) as first salvage regimen in chronic lymphocytic leukemia (CLL). In an intention-to-treat analysis including 237 patients, the median progression-free survival (PFS) was 25 months. The presence of del (17p), unmutated IGHV and advanced stage were associated with a shorter PFS at multivariate analysis. The median time-to-next treatment was 31.3 months. Front-line treatment with a chemoimmunotherapy regimen was the only predictive factor for a shorter time to next treatment at multivariate analysis. The median overall survival (OS) was 74.5 months. Advanced disease stage (i.e. Rai stage III-IV or Binet stage C) and resistant disease were the only parameters significantly associated with a shorter OS. Grade 3-5 infections were recorded in 6.3% of patients. A matched-adjusted indirect comparison with ibrutinib given second-line within Named Patient Programs in the United Kingdom and in Italy was carried out with OS as objective end point. When restricting the analysis to patients with intact 17p who had received chemoimmunotherapy in first line, there was no difference in OS between patients treated with ibrutinib (63% alive at 36 months) and patients treated with BR (74.4% alive at 36 months). BR is an efficacious first salvage regimen in CLL in a real-life population, including the elderly and unfit patients. BR and ibrutinib may be equally effective in terms of OS when used as first salvage treatment in patients without 17p deletion. (Registered at clinicaltrials.gov identifier: 02491398)

Allogeneic stem cell transplantation in mantle cell lymphoma in the era of new drugs and CAR-T cell therapy

MCL is an uncommon lymphoproliferative disorder that has been regarded as incurable since its identification as a distinct entity. Allogeneic transplantation for two decades has represented the only option capable of ensuring prolonged remissions and possibly cure. Despite its efficacy, its application has been limited by feasibility limitations and substantial toxicity, particularly in elderly patients. Nevertheless, the experience accumulated over time has been wide though often scattered among retrospective and small prospective studies. In this review, we aimed at critically revise and discuss available evidence on allogeneic transplantation in MCL, trying to put available evidence into the 2020 perspective, characterized by unprecedented development of novel promising therapeutic agents and regimens

A medical device containing purified bovine colostrum ( M

Objective This study assessed the effectiveness and safety of a medical device containing purified bovine colostrum (Monurelle Biogel; Zambon, Bresso, Italy) in improving vulvovaginal atrophy (VVA), sexual function, urinary symptoms, and quality of life (QoL) in postmenopausal women. Methods In all, 172 postmenopausal women with VVA were included in the study. All women were treated with vaginal Monurelle Biogel daily for 12 weeks. Patients underwent clinical examinations, completed a 3-day voiding diary, and had VVA graded using the Vaginal Health Index (VHI) at baseline and 12 weeks. Patients also completed the Female Sexual Function Index (FSFI), overactive bladder questionnaire (OAB-Q), and the Urogenital Distress Inventory (UDI-6), among others. Results After 12 weeks, there were significant increases in mean (+/- SD) VHI (12.53 +/- 3.67 vs. 19.31 +/- 3.49; P < .0001), the number of patients engaging in regular sexual activity 102 (59.3%) vs. 144 (83.7%), and in the total FSFI score (21.64 +/- 2.99 vs. 28.16 +/- 1.93; P < .0001) compared with baseline. In addition, there were significant reductions in the mean number of 24-hour voids (9.57 +/- 2.12 vs. 7.13 +/- 1.22; P < .0001), urgent micturition episodes per 24 hours (1.75 +/- 0.76 vs. 1.14 +/- 0.87; P = .001), nocturia episodes (1.58 +/- 0.85 vs. 0.97 +/- 1.18; P = .0002), and urinary incontinence episodes per 24 hours (0.74 +/- 0.59 vs. 0.28 +/- 0.52; P = .003). Finally, after 12 weeks treatment, there were significant differences in UDI-6 (7.85 +/- 0.81 vs. 5.56 +/- 1.40), OAB-Q symptom (53.60 +/- 12.57 vs. 22.08 +/- 9.63), and OAB-Q health-related QoL (21.75 +/- 8.51 vs. 69.34 +/- 14.59) scores compared with baseline (P < .0001 for all). The Patient Impression of Global Improvement scale revealed global improvement in 143 women (83.14%). Conclusions Monurelle Biogel is an effective treatment for VVA in postmenopausal women, improving sexual life, urinary symptoms, and QoL